WO1997031114A2 - Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus - Google Patents

Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus Download PDF

Info

Publication number
WO1997031114A2
WO1997031114A2 PCT/GB1997/000524 GB9700524W WO9731114A2 WO 1997031114 A2 WO1997031114 A2 WO 1997031114A2 GB 9700524 W GB9700524 W GB 9700524W WO 9731114 A2 WO9731114 A2 WO 9731114A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
dna
sequence
binding
Prior art date
Application number
PCT/GB1997/000524
Other languages
English (en)
Other versions
WO1997031114A3 (fr
Inventor
Martin Karl Russell Burnham
John Edward Hodgson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to EP97905269A priority Critical patent/EP0822987A2/fr
Priority to JP9529922A priority patent/JPH11506022A/ja
Publication of WO1997031114A2 publication Critical patent/WO1997031114A2/fr
Publication of WO1997031114A3 publication Critical patent/WO1997031114A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides and recombinant host cells transformed with the polynucleotides .
  • This invention also relates to inhibiting the biosynthesis or action of such polypeptides and to the use of inhibitors in therapy .
  • Staphylococci make up a medically important genera of microbes . They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues Staphlococc ⁇ s aitreus is the second leading cause of bacteremia in cancer patients.
  • Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common.
  • the manifestation of these diseases result from the actions of exotoxms as opposed to tissue invasion and bacteremi. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome .
  • Staphylococcal proteins associated with pathogenicity have been identified, e.g., coaguiase, hemolysms, leucocidins and exo and enterotoxins, very little is known concerning the temporal expression of genes of bacterial pathogens during infection and disease progression in a mammalian host.
  • the present invention employs a novel technology to determine gene expression in the pathogen at different stages of infection of the mammalian host.
  • a novel aspect of this invention is the use of a suitably labelled oligonucleotide probe which anneals specifically to the bacterial ribosomal RNA in Northern blots of bacterial RNA preparations from infected tissue.
  • a suitably labelled oligonucleotide probe which anneals specifically to the bacterial ribosomal RNA in Northern blots of bacterial RNA preparations from infected tissue.
  • the invention provides a method of identifying genes transcribed in an organism in infected host tissue by identifying mRNA present using RT- PCR, characterised in that a bacterial mRNA preparation is obtained from total RNA from infected tissue by enriching for bacterial RNA by a suitable bacterial disruption technique in order to selectively damage mammalian RNA and at the same time give sufficient quantities of bacterial RNA for RT-PCR, and wherein the conditions for selectively enriching for bacterial RNA are determined by probing with an oligonucleotide probe specific to bacterial ribosomal RNA.
  • This process of optimisation preferably uses a unique labelled oligonucleotide probe to bacterial ribosomal RNA which is used in Northern experiments against the experimental RNA preparations to determine those conditions which give optimal levels of bacterial RNA.
  • bacterial ribosomal RNA is present at 2-4 orders of magnitude in amount to bacterial mRNA species this detection procedure provides a suitably sensitive indication to the existence and quantity of bacterial RNA in the presence of the vastly greater levels of mammalian RNA from the infected tissue.
  • This detection system may be used in conjunction with the visualisation of total RNA by ethidium bromide staining of 1% agarose gels on which it has been run out . On these gels mammalian ribosomal RNA migrates at a different rate to bacterial ribosomal RNA and so can be identified.
  • a suitable oligonucleotide useful for applying this method to genes expressed in Staphylococcus aureus is 5'-gctcctaaaaggttactccaccggc-3' [SEQ ID NO:91].
  • the present invention provides a polynucleotide having the DNA sequence given in any of sequences set forth in, or selected from the group consisting essentially of,
  • the invention further provides a polynucleotide encoding a protein from S. aureus WCUH 29 and characterized in that it comprises the DNA sequence given in any of sequences set forth in SEQUENCE 1 [SEQ ID Nos:
  • the present invention also provides a novel protein from Staphylococcus. aureus WCUH29 obtainable by expression of a gene characterised in that it comprises the DNA sequence given in any of sequences set forth in SEQUENCE 1 [SEQ ID Nos: 1,4,7,10, 13,16,19,22,25,28,31 ,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76] of Table 1, or a fragment, analogue or derivative thereof.
  • the present invention further relates to a novel protein from Staphylococcus.
  • aureus WCUH29 characterised in that it comprises the amino acid sequence given in any of the sequences set forth in, or selected from the group consisting essentially of, SEQUENCE 2 [SEQ ID Nos: 79,80,81 ,82,83,84,85.86,87,88,89,90] of Table 1, or a fragment, analogue or derivative thereof.
  • the invention also relates to a polypeptide fragment of the protein, having the amino acid sequence given in any of the sequences set forth in SEQUENCE 2 [SEQ ID Nos: 79,80,81 ,82,83,84,85,86,87,88,89,90] of Table 1, or a derivative thereof.
  • polypeptide(s) will be used to refer to the protein and its fragments, analogues or derivatives.
  • polynucleotides (DNA or RNA) which encode such polypeptides.
  • the invention also relates to novel oligonucleotides, including the sequences set forth in SEQUENCE 3 [SEQ ID Nos: 2,5,8,11 ,14,17,20,23,26,29,32,35,38,41 ,44,47, 50,53,56,59,62,65,68,71 ,74,77] and 4 [SEQ ID Nos: 3,6,9,12,15, 18,21,24,27,30, 33,36,39,42,45,48,51,54,57,60.63,66,69,72,75,78] of Table 1 , derived from the sequences set forth in SEQUENCE 1 [SEQ ID Nos: 1 ,4,7,10,13,16,19.22,25,28,31,34, 37,40,43,46,49,52,55,58,61,64,67,70,73,76] of Table 1 which can act as PCR primers in the process herein described to determine whether or not the Staphylococcus aureus genes
  • Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds.
  • the encoded protein upon expression can be used as a target for the screening of antibacterial drugs.
  • the DNA sequences encoding regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
  • many of the sequences disclosed herein also provide regions upstream and downstream from the encoding sequence. These sequences are useful as a source of regulatory elements for the control of bacterial gene expression. Such sequences are conveniently isolated by restriction enzyme action or synthesized chemically and introduced, for example, into promoter identification strains.
  • strains contain a reporter structural gene sequence located downstream from a restriction site such that if an active promoter is inserted, the reporter gene will be expressed.
  • this invention also provides several means for identifying particularly useful target genes. The first of these approaches entails searching appropriate databases for sequence matches. Thus, if a homoiogue exists, the Staphylococcal-like form of this gene would likely play an analogous role. For example, a Staphylococcal protein identified as homologous to a cell surface protein in another organism would be useful as a vaccine candidate. To the extent such homologies have been identified for the sequences disclosed herein they are reported along with the encoding sequence.
  • a library of clones of chromosomal DNA of S.aureus WCUH 29 in E.coli or some other suitable host is probed with a radiolabelled oligonucleotide, preferably a 17mer or longer, derived from the partial sequence.
  • Clones carrying DNA identical to that of the probe can then be distinguished using high stringency washes.
  • sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone.
  • a polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA.
  • the DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.
  • the coding sequence which encodes the polypeptide may be identical to the coding sequence of any of the sequences of SEQUENCE 1 [SEQ ID Nos: 1 ,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61 ,64,67,70,73,76] of Table 1 or may be a different coding sequence which coding sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same polypeptide.
  • the present invention includes variants of the hereinabove described
  • polynucleotides which encode fragments, analogues and derivatives of the polypeptides of the invention, and in particular polypeptides characterized by the deduced amino acid sequences set forth in each SEQUENCE 2 [SEQ ID Nos: 79,80,81,82,83,84, 85,86,87,88.89,90] of Table 1.
  • the variant of the polynucleotide may be a naturally occurring allelic variant of the polynucleotide or a non-naturally occurring variant of the polynucleotide.
  • the present invention includes polynucleotides encoding the same polypeptides of the invention, and in particular characterized by the deduced amino acid sequences set forth in each SEQUENCE 2 [SEQ ID Nos: 79,80,81 ,82,83,84,85,86,87, 88,89,90] of Table 1 as well as variants of such polynucleotides which variants encode for a fragment, derivative or analogue of the polypeptide.
  • nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
  • the polynucleotide may have a coding sequence which is a naturally occurring allelic variant of the coding sequence characterized by the DNA sequence of any of the sequences set forth in Table 1 as SEQUENCE 1 [SEQ ID Nos: 1,4,7,10,13,16,19,22.25, 28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76].
  • an allelic variant is an alternate form of a polynucleotide sequence which may have a substitution, deletion or addition of one or more nucleotides, which does not substantially alter the function of the encoded polypeptide.
  • the polynucleotide which encodes for the mature polypeptide may include only the coding sequence for the mature polypeptide or the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence.
  • polynucleotide encoding a polypeptide encompasses a polynucleotide which includes only coding sequence for the polypeptide as well as a polynucleotide which includes additional coding and/or non-coding sequence.
  • the present invention therefore includes polynucleotides, wherein the coding sequence for the mature polypeptide may be fused in the same reading frame to a polynucleotide sequence which aids in expression and secretion of a polypeptide from a host cell, for example, a leader sequence which functions as a secretory sequence for controlling transport of a polypeptide from the cell.
  • the polypeptide having a leader sequence is a preprotein and may have the leader sequence cleaved by the host cell to form the mature form of the polypeptide.
  • the polynucleotides may also encode for a proprotein which is the mature protein plus additional 5' amino acid residues.
  • a mature protein having a prosequence is a proprotein and is an inactive form of the protein.
  • the polynucleotide of the present invention may encode for a mature protein, or for a protein having a prosequence or for a protein having both a prosequence and a presequence (leader sequence).
  • leader sequence the amino acid sequences provided herein show a methionine residue at the NH 2 -terminus. It is appreciated, however, that during post-translational modification of the peptide, this residue may be deleted. Accordingly, this invention contemplates the use of both the sequences.
  • An expression vector is constructed so that the particular coding sequence is located in the vector with the appropriate regulatory sequences, the positioning and orientation of the coding sequence with respect to the control sequences being such that the coding sequence is transcribed under the "control" of the control sequences (i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence).
  • control i.e., RNA polymerase which binds to the DNA molecule at the control sequences transcribes the coding sequence.
  • Modification of the coding sequences may be desirable to achieve this end. For example, in some cases it may be necessary to modify the sequence so that it may be attached to the control sequences with the appropriate orientation; i.e., to maintain the reading frame.
  • control sequences and other regulatory sequences may be ligated to the coding sequence prior to insertion into a vector, such as the cloning vectors described above.
  • a vector such as the cloning vectors described above.
  • the coding sequence can be cloned directly into an expression vector which already contains the control sequences and an appropriate restriction site.
  • recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coll and S. cerevisiae TRP1 gene, and a promoter derived from a highly- expressed gene to direct transcription of a downstream structural sequence.
  • the heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the peripiasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.
  • the vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein.
  • the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
  • the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
  • the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
  • a promoter operably linked to the sequence.
  • Bacterial pET-3 vectors (Stratagene), pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).
  • Eukaryotic pBlueBacIII (Invitrogen), pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia).
  • any other plasmid or vector may be used as long as they are replicable and viable in the host.
  • Examples of recombinant DNA vectors for cloning and host cells which they can transform include the bacteriophage ⁇ (E. colt), pBR322 (E. coli), pACYC177 (E. coli), pKT230 (gram-negative bacteria), pGV1 106 (gram-negative bacteria), pLAFR1 (gram- negative bacteria), pME290 (non-E. coli gram-negative bacteria), pHV14 (E.
  • the polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence at either the 5' or 3' terminus of the gene which allows for purification of the polypeptide of the present invention.
  • the marker sequence may be a hexa-histidine tag supplied by the pQE series of vectors (supplied commercially by Quiagen Inc.) to provide for purification of the polypeptide fused to the marker in the case of a bacterial host.
  • the present invention further relates to polynucleotides which hybridize to the hereinabove-described sequences if there is at least 50% and preferably at least 70% identity between the sequences.
  • the present invention particularly relates to
  • Staphylococcal polynucleotides which hybridize under stringent conditions to the hereinabove-described polynucleotides .
  • stringent conditions means hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences.
  • the polynucleotides which hybridize to the hereinabove described polynucleotides in a preferred embodiment encode polypeptides which retain substantially the same biological function or activity as the polypeptide of the invention.
  • a preferred embodiment of the invention is a polynucleotide having at least a 70%, 80%, 90% or 95% identity to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting essentially of SEQ ID Nos:
  • fragment when referring to the polypeptide of the invention, means a polypeptide which retains essentially the same biological function or activity as such polypeptide.
  • an analogue includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide.
  • the polypeptide of the present invention may be a recombinant polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.
  • the fragment, derivative or analogue of the polypeptide of the invention may be (i) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the polypeptide is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glyeol), or (iv) one in which the additional amino acids are fused to the polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the polypeptide or a proprotein sequence.
  • Such fragments, derivatives and analogues are deemed to be within the scope of those skilled in the art from the teachings herein.
  • polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.
  • isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
  • a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
  • Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
  • the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
  • polypeptide of the invention by recombinant techniques by expressing a polynucleotide encoding said polypeptide in a host and recovering the expressed product.
  • polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.
  • Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
  • the vector may be, for example, in the form of a plasmid, a cosmid, a phage, etc.
  • the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes.
  • the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • Suitable expression vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA.
  • any other vector may be used as long as it is replicable and viable in the host.
  • the appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art.
  • the DNA sequence in the expression vector is operativeiy linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis.
  • promoter for example, LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda P L promoter and other promoters known to control expression of genes in eukaryotic or prokaryotic cells or their viruses.
  • the expression vector also contains a ribosome binding site for translation initiation and a transcription terminator.
  • the vector may also include appropriate sequences for amplifying expression.
  • the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofoiate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.
  • the gene can be placed under the control of a promoter, ribosome binding site (for bacterial expression) and, optionally, an operator (collectively referred to herein as "control" elements), so that the DNA sequence encoding the desired protein is transcribed into RNA in the host cell transformed by a vector containing this expression construction.
  • the coding sequence may or may not contain a signal peptide or leader sequence.
  • the polypeptides of the present invention can be expressed using, for example, the E. coli tac promoter or the protein A gene (spa) promoter and signal sequence. Leader sequences can be removed by the bacterial host in post-translational processing. See, e.g., U.S. Patent Nos. 4,431,739; 4,425,437; 4,338,397.
  • Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers.
  • Two appropriate vectors are PKK232-8 and PCM7.
  • Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P R , P L and trp.
  • Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.
  • regulatory sequences which allow for regulation of the expression of the protein sequences relative to the growth of the host cell.
  • Regulatory sequences are known to those of skill in the art, and examples include those which cause the expression of a gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
  • Other types of regulatory elements may also be present in the vector, for example, enhancer.
  • sequences which cause the secretion of the polypeptide from the host organism may be desirable to add sequences which cause the secretion of the polypeptide from the host organism, with subsequent cleavage of the secretory signal.
  • Polypeptides can be expressed in host cells under the control of appropriate promoters.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.
  • Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., ( 1989), the disclosure of which is hereby incorporated by reference.
  • the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
  • Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.
  • Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.
  • the polypeptide of the present invention may be produced by growing host cells transformed by an expression vector described above under conditions whereby the polypeptide of interest is expressed. The polypeptide is then isolated from the host cells and purified. If the expression system secretes the polypeptide into growth media, the polypeptide can be purified directly from the media. If the polypeptide is not secreted, it is isolated from cell lysates or recovered from the ceil membrane fraction. Where the polypeptide is localized to the cell surface, whole cells or isolated membranes can be used as an assayable source of the desired gene product. Polypeptide expressed in bacterial hosts such as E. coli may require isolation from inclusion bodies and refolding.
  • the mature protein has a very hydrophobic region which leads to an insoluble product of overexpression
  • the selection of the appropriate growth conditions and recovery methods are within the skill of the art.
  • the polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulphate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
  • HPLC high performance liquid chromatography
  • polypeptides of the present invention may be glycosylated or may be non-glycosylated.
  • Polypeptides of the invention may also include an initial methionine amino acid residue.
  • a “replicon” is any genetic element (e.g., plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo; i.e., capable of replication under its own control.
  • a “vector” is a replicon, such as a plasmid, phage, or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
  • double-stranded DNA molecule refers to the polymeric form of
  • deoxyribonucleotides bases adenine, guanine, thymine, or cytosine
  • bases adenine, guanine, thymine, or cytosine bases adenine, guanine, thymine, or cytosine
  • This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes.
  • sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand having the sequence homologous to the mRNA).
  • a DNA "coding sequence of or a "nucleotide sequence encoding" a particular protein is a DNA sequence which is transcribed and translated into a polypeptide when placed under the control of appropriate regulatory sequences.
  • a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence.
  • the promoter sequence is bound at the 3' terminus by a translation start codon (e.g., ATG) of a coding sequence and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
  • a transcription initiation site (conveniently defined by mapping with nuclease S 1 ), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
  • Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT” boxes.
  • Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the - 10 and -35 consensus sequences.
  • control sequences refers collectively to promoter sequences, ribosome binding sites, polyadenylation signals, transcription termination sequences, upstream regulatory domains, enhancers, and the like, which collectively provide for the expression (i.e., the transcription and translation) of a coding sequence in a host cell.
  • a control sequence "directs the expression" of a coding sequence in a cell when RNA polymerase will bind the promoter sequence and transcribe the coding sequence into mRNA, which is then translated into the polypeptide encoded by the coding sequence.
  • a "host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous DNA sequence.
  • a cell has been "transformed" by exogenous DNA when such exogenous DNA has been introduced inside the cell membrane.
  • Exogenous DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
  • the exogenous DNA may be maintained on an episomal element, such as a plasmid.
  • a stably transformed or transfected cell is one in which the exogenous DNA has become integrated into the chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cell containing the exogenous DNA.
  • a “clone” is a population of cells derived from a single cell or common ancestor by mitosis.
  • a “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
  • a "heterologous" region of a DNA construct is an identifiable segment of DNA within or attached to another DNA molecule that is not found in association with the other molecule in nature.
  • a polypeptide of the invention for therapeutic or prophylactic purposes, for example, as an antibacterial agent or a vaccine.
  • a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunisation.
  • inhibitors to such polypeptides useful as antibacterial agents.
  • antibodies against such polypeptides are provided.
  • Another aspect of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising the above polypeptide, polynucleotide or inhibitor of the invention and a pharmaceutically acceptable carrier.
  • the invention provides the use of an inhibitor of the invention as an antibacterial agent.
  • the invention further relates to the manufacture of a medicament for such uses.
  • the polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which have anti-bacterial action.
  • the polypeptides or ceils expressing them can be used as an immunogen to produce antibodies thereto.
  • These antibodies can be, for example, polyclonal or monoclonal antibodies.
  • the term antibodies also includes chimerie, single chain, and humanized antibodies, as well as Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of such antibodies and fragments.
  • Antibodies generated against the polypeptides of the present invention can be obtained by direct injection of the polypeptides into an animal or by administering the polypeptides to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptides itself. In this manner, even a sequence encoding only a fragment of the polypeptides can be used to generate antibodies binding the whole native polypeptides. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
  • Polypeptide derivatives include antigenically or immunologically equivalent derivatives which form a particular aspect of this invention.
  • the term 'antigenically equivalent derivative' as used herein encompasses a polypeptide or its equivalent which will be specifically recognised by certain antibodies which, when raised to the protein or polypeptide according to the present invention, interfere with the interaction between pathogen and mammalian host.
  • the term 'immunologically equivalent derivative' as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.
  • derivatives which are slightly longer or slightly shorter than the native protein or polypeptide fragment of the present invention may be used.
  • polypeptides in which one or more of the amino acid residues are modified may be used.
  • Such peptides may, for example, be prepared by substitution, addition, or rearrangement of amino acids or by chemical modification thereof. All such substitutions and modifications are generally well known to those skilled in the art of peptide chemistry.
  • the polypeptide such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
  • the fusion protein may provide stability to the polypeptide.
  • the antigen may be associated, for example by conjugation , with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH).
  • BSA bovine serum albumin
  • KLH keyhole limpet haemocyanin
  • a multiple antigenic peptide comprising multiple copies of the the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.
  • any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, Nature, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • 4,946,778 can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.
  • antibody-containing cells from the immunised mammal are fused with myeloma cells to create hybridoma cells secreting monoclonal antibodies.
  • the hybridomas are screened to select a cell line with high binding affinity and favorable cross reaction with other staphylococcal species using one or more of the original polypeptide and/or the fusion protein.
  • the selected cell line is cultured to obtain the desired Mab.
  • Hybridoma cell lines secreting the monoclonal antibody are another aspect of this invention.
  • phage display technology could be utilised to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v- genes of lymphocytes from humans screened for possessing anti-Fbp or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (,992) Biotechnology 10, 779-783).
  • the affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).
  • the antibody should be screened again for high affinity to the polypeptide and/or fusion protein.
  • a fragment of the final antibody may be prepared.
  • the antibody may be either intact antibody of M r approx 150,000 or a derivative of it, for example a Fab fragment or a Fv fragment as described in Skerra, A and Pluckthun , A (1988) Science 240 1038-1040. If two antigen binding domains are present each domain may be directed against a different epitope - termed 'bispecific' antibodies.
  • the antibody of the invention may be prepared by conventional means for example by established monoclonal antibody technology (Kohler, G. and Milstein, C. supra (1975)) or using recombinant means e.g. combinatorial libraries, for example as described in Huse W.D. et al., (1989) Science 246,1275- 1281.
  • the antibody is prepared by expression of a DNA polymer encoding said antibody in an appropriate expression system such as described above for the expression of polypeptides of the invention.
  • the choice of vector for the expression system will be determined in part by the host, which may be a prokaryotic cell, such as E. coli (preferably strain B) or Streptomyces sp. or a eukaryotic cell, such as a mouse C127, mouse myeloma, human HeLa, Chinese hamster ovary, filamentous or unicellular fungi or insect cell.
  • the host may also be a transgenic animal or a transgenic plant [for example as described in Hiatt,A et al.(1989) Nature 34, 76-78].
  • Suitable vectors include plasmids, bacteriophages cosm,ds and recombinant viruses, derived from, for example, baculoviruses and vaccinia.
  • the Fab fragment may also be prepared from its parent monoclonal antibody by enzyme treatment, for example using papain to cleave the Fab portion from the Fc portion.
  • the antibody or derivative thereof is modified to make it less immunogenic in the patient.
  • the patient is human the antibody may most preferably be 'humanised'; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al (1986), Nature 321, 522-525 or Tempest et al.,( 1991 ) Biotechnology 9, 266-273.
  • the modification need not be restricted to one of 'humanisation' ; other primate sequences (for example Newman, R. et al . 1992, Biotechnology,10, 1455- 1460) may also be used.
  • the humanised monoclonal antibody, or its fragment having binding activity, form a particular aspect of this invention.
  • This invention provides a method of screening drugs to identify those which interfere with the proteins herein, which method comprises measuring the interference of the protein activity by test drug. For example, if the protein has enzymatic activity, after suitable purification and formulation the activity of the enzyme can be followed by its ability to convert its natural substrates. By incorporating different chemically synthesised test compounds or natural products into such an assay of enzymatic activity one is able to detect those additives which compete with the natural substrate or otherwise inhibit enzymatic activity.
  • the invention also relates to inhibitors identified thereby.
  • a polynucleotide of the invention in genetic immunisation will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1 :363, Manthorpe et al., Hum. Gene Ther.
  • Suitable promoters for muscle transfection include CMV, RSV, SRa, actin, MCK, alpha globin, adenovirus and dihydrofolate reductase.
  • the active agent i.e the polypeptide, polynucleotide or inhibitor of the invention, may be administered to a patient as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.
  • the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
  • Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
  • Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.
  • the daily dosage level of the active agent will be from 0.01 to 10 mg/kg, typically around 1 mg/kg.
  • the physician in any event will determine the actual dosage which will be most suitable for an individual patient and will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • a vaccine composition is conveniently in injectable form.
  • Conventional adjuvants may be employed to enhance the immune response.
  • a suitable unit dose for vaccination is 0.5-5ug/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.
  • Plasmids are designated by a lower case p preceded and/or followed by capital letters and/or numbers.
  • the starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accord with published procedures.
  • equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.
  • “Digestion” of DNA refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA.
  • the various restriction enzymes used herein are commercially available and their reaction conditions, cofactors and other requirements were used as would be known to the ordinarily skilled artisan.
  • For analytical purposes typically 1 ⁇ g of plasmid or DNA fragment is used with about 2 units of enzyme in about 20 ⁇ l of buffer solution.
  • For the purpose of isolating DNA fragments for plasmid construction typically 5 to 50 ⁇ g of DNA are digested with 20 to 250 units of enzyme in a larger volume. Appropriate buffers and substrate amounts for particular restriction enzymes are specified by the manufacturer. Incubation times of about 1 hour at 37 C are ordinarily used, but may vary in accordance with the supplier's instructions. After digestion the reaction is electrophoresed directly on a polyacrylamide gel to isolate the desired fragment.
  • Oligonucleotides refers to either a single stranded polydeoxynucleotide or two complementary polydeoxynucleotide strands which may be chemically synthesized. Such synthetic oligonucleotides have no 5' phosphate and thus will not ligate to another oligonucleotide without adding a phosphate with an ATP in the presence of a kinase. A synthetic oligonucleotide will ligate to a fragment that has not been dephosphorylated.
  • Ligase refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (Maniatis, T., et al., Id., p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with 10 units to T4 DNA ligase ("ligase”) per 0.5 ⁇ g of approximately equimoiar amounts of the DNA fragments to be ligated.
  • ligase T4 DNA ligase
  • the polynucleotide having the DNA sequence given in SEQ ID NO 1 was obtained from a library of clones of chromosomal DNA of S.aureus WCUH 29 in E.coli. In some cases the sequencing data from two or more clones containing overlapping S.aureus WCUH 29 DNA was used to construct the contiguous DNA sequence in Sequences set forth in SEQUENCE 1 [SEQ ID Nos: 1,4,7,10,13,16, 19,22.25,28,31 ,34,37,40,43,46, 49,52,55,58,61,64,67,70,73,76] of Table 1. Libraries may be prepared by routine methods, for example:
  • Total cellular DNA is isolated from Staphylococcus aureus strain WCUH29 (NCIMB 40771 ) according to standard procedures and size-fractionated by either of two methods.
  • Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures.
  • DNA fragments of up to 1 1 kbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • Total cellular DNA is partially hydrolysed with a combination of four restriction enzymes (Rsal, Pall, AIuI and Bsh1235I) and size- fractionated according to standard procedures.
  • EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • Necrotic fatty tissue from a four day groin infection of Staphylococcus aureus WCUH29 in the mouse is efficiently disrupted and processed in the presence of chaotropic agents and RNAase inhibitor to provide a mixture of animal and bacterial RNA.
  • the optimal conditions for disruption and processing to give stable preparations and high yields of bacterial RNA are followed by the use of hybridisation to a radiolabelled oligonucleotide specific to Staphylococcus aureus 16S RNA on Northern blots.
  • the RNAase free, DNAase free, DNA and protein free preparations of RNA obtained are suitable for Reverse
  • RT-PCR Transcription PCR
  • mice 10 ml. volumes of sterile nutrient broth (No.2 Oxoid) are seeded with isolated, individual colonies of Staphylococcus aureus WCUH29 from an agar culture plate. The cultures are incubated aerobicaliy (static culture) at 37 degrees C for 16-20 hours . 4 week old mice (female, 18g-22g, strain MF1) are each infected by subcutaneous injection of 0.5ml. of this broth culture of Staphylococcus aureus WCUH29 (diluted in broth to approximately 10 8 cfu/ml.) into the anterior , right lower quadrant (groin area). Mice should be monitored regularly during the first 24 hours after infection, then daily until termination of study. Animals with signs of systemic infection, i.e. lethargy, ruffled appearance, isolation from group, should be monitored closely and if signs progress to moribundancy, the animal should be culled immediately.
  • systemic infection i.e. lethargy, ruffled appearance
  • mice are killed using carbon dioxide asphyxiation. To minimise delay between death and tissue processing /storage, mice should be killed individually rather than in groups. The dead animal is placed onto its back and the fur swabbed liberally with 70% alcohol. An initial incision using scissors is made through the skin of the abdominal left lower quadrant, travelling superiorly up to, then across the thorax. The incision is completed by cutting inferiorly to the abdominal lower right quadrant. Care should be taken not to penetrate the abdominal wall. Holding the skin flap with forceps, the skin is gently pulled way from the abdomen. The exposed abscess, which covers the peritoneal wall but generally does not penetrate the muscle sheet completely, is excised, taking care not to puncture the viscera
  • the abscess/muscle sheet and other infected tissue may require cutting in sections, prior to flash-freezing in liquid nitrogen, thereby allowing easier storage in plastic collecting vials.
  • tissue samples (each approx 0.5-0.7g) in 2ml screw-cap tubes are removed from -80°C.storage into a dry ice ethanol bath
  • the samples are disrupted individually whilst the remaining samples are kept cold in the dry ice ethanol bath.
  • TRIzol Reagent Gibco BRL, Life Technologies
  • the lid is replaced taking care not to get any beads into the screw thread so as to ensure a good seal and eliminate aerosol generation.
  • the sample is then homogenised in a Mini-BeadBeater Type BX-4 (Biospec Products).
  • Necrotic fatty tissue is treated for 100 seconds at 5000 rpm in order to achieve bacterial lysis. In vivo grown bacteria require longer treatment than in vitro grown S.aureus WCUH29 which are disrupted by a 30 second bead-beat.
  • the tubes After bead-beating the tubes are chilled on ice before opening in a fume-hood as heat generated during disruption may degrade the TRIzol and release cyanide.
  • RNA extraction is then continued according to the method given by the manufacturers of TRIzol Reagent i.e.:-
  • the aqueous phase approx 0.6 ml, is transferred to a sterile eppendorf tube and 0.5 ml of isopropanol is added.
  • the samples are spun at 12,000 x g, 4 °C for 10 minutes. The supernatant is removed and discarded then the RNA pellet is washed with 1 ml 75% ethanol.
  • RNA preparations are stored at -80 °C for up to one month.
  • the RNA precipitate can be stored at the wash stage of the protocol in 75% ethanol for at least one year at -20 °C.
  • RNA isolation Quality of the RNA isolated is assessed by running samples on 1% agarose gels. 1 x TBE gels stained with ethidium bromide are used to visualise total RNA yields.
  • 2.2M formaldehyde gels are run and vacuum blotted to Hybond-N (Amersham). The blot is then hybridised with a 32 P labelled oligonucletide probe specific to 16s rRNA of S.aureus ( K.Greisen, M. Loeffelholz, A. Purohit and D. Leong. J.CIin. ( 1994) Microbiol. 32 335-351 ).
  • the size of the hybridising band is compared to that of control RNA isolated from in vitro grown S.aureus WCUH29 in the Northern blot. Correct sized bacterial 16s rRNA bands can be detected in total RNA samples which show extensive degradation of the mammalian RNA when visualised on TBE gels.
  • DNA was removed from 73 microlitre samples of RNA by a 15 minute treatment on ice with 3 units of DNAasel, amplification grade (Gibco BRL, Life Technologies) in the buffer supplied with the addition of 200 units of Rnasin (Promega) in a final volume of 90 microlitres.
  • the DNAase was inactivated and removed by treatment with TRIzol LS Reagent (Gibco BRL, Life Technologies) according to the manufacturers protocol.
  • DNAase treated RNA was resuspended in 73 microlitres of DEPC treated water with the addition of Rnasin as described in Method 1.
  • PCR reactions are set up on ice in 0.2ml tubes by adding the following
  • PCR reactions are run on a Perkin Elmer GeneAmp PCR System 9600 as follows: 5 minutes at 95 °C, then 50 cycles of 30 seconds each at 94 °C, 42 °C and 72°C followed by 3 minutes at 72 °C and then a hold temperature of 4 °C. (the number of cycles is optimally 30-50 to determine the appearance or lack of a PCR product and optimally 8-30 cycles if an estimation of the starting quantity of cDNA from the RT reaction is to be made).
  • PCR product 10 microlitre aliquots are then run out on 1% 1 x TBE gels stained with ethidium bromide with PCR product, if present, sizes estimated by comparison to a 100 bp DNA Ladder (Gibco BRL, Life Technologies).
  • a labelled PCR primer e.g. labelled at the 5'end with a dye
  • a suitable aliquot of the PCR product is run out on a polyacrylamide sequencing gel and its presence and quantity detected using a suitable gel scanning system (e.g. ABI Prism TM 377 Sequencer using GeneScan TM software as supplied by Perkin Elmer)
  • RT/PCR controls may include +/- reverse transcriptase reactions, 16s rRNA primers or DNA specific primer pairs designed to produce PCR products from non- transcribed S.aureus WCUH29 genomic sequences.
  • PCR reactions are set up and run as described above using approx. 1 microgram of DNA in place of the cDNA and 35 cycles of PCR.
  • RT/PCR are PCR failures and as such are uni ⁇ formative. Of those which give the correct size product with DNA PCR two classes are distinguished in RT/PCR:
  • RT/PCR show a stronger signal in the +RT samples than the signal (if at all present) in -RT controls.
  • nucleotide sequences set forth in SEQUENCE 1 [SEQ ID Nos: 1,4,7,10,13,16,19,22,25,28,31,34,37,40,43,46,49,52,55,58,61,64,67,70,73,76] of Table 1 ) were identified in the above test as transcribed in vivo. Each set of sequences relates to a separate gene (Gene #). Deduced amino acid sequences are given where available as the sequences set forth in each SEQUENCE 2 [SEQ ID Nos:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polynucléotides staphylococciques, des polypeptides codés par des polynucléotides de ce type, l'utilisation de ces polynucléotides et de ces polypeptides. L'invention a aussi pour objet la production de ces polynucléotides et de ces polypeptides et de cellules hôtes de recombinaison transformées par les polynucléotides. L'invention traite également de l'inhibition de la biosynthèse ou de l'action de ces polynucléotides ou polypeptides et de l'utilisation de ces inhibiteurs dans des applications thérapeutiques.
PCT/GB1997/000524 1996-02-26 1997-02-25 Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus WO1997031114A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP97905269A EP0822987A2 (fr) 1996-02-26 1997-02-25 Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus
JP9529922A JPH11506022A (ja) 1996-02-26 1997-02-25 スタフィロコッカス・アウレウス由来のポリヌクレオチドおよびアミノ酸配列

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9604045.6A GB9604045D0 (en) 1996-02-26 1996-02-26 Novel compounds
GB9604045.6 1996-02-26

Publications (2)

Publication Number Publication Date
WO1997031114A2 true WO1997031114A2 (fr) 1997-08-28
WO1997031114A3 WO1997031114A3 (fr) 1997-10-23

Family

ID=10789423

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/000524 WO1997031114A2 (fr) 1996-02-26 1997-02-25 Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus

Country Status (4)

Country Link
EP (1) EP0822987A2 (fr)
JP (1) JPH11506022A (fr)
GB (1) GB9604045D0 (fr)
WO (1) WO1997031114A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0892064A2 (fr) * 1997-06-04 1999-01-20 Smithkline Beecham Corporation Polypeptides recombinants secA2 de Staphylococcus aureus et leurs utilisations
WO1999018117A1 (fr) * 1997-10-03 1999-04-15 Smithkline Beecham Corporation 3-hydroxyacyl-coa deshydrogenase due au staphylococcus aureus
EP0913474A2 (fr) * 1997-10-28 1999-05-06 Smithkline Beecham Corporation Dbpa, une hélicase de Staphylococcus aureus
US6403337B1 (en) 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
WO2003080865A1 (fr) * 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research Amorces pour detecter des bacteries qui contaminent des aliments, et leur utilisation
US6632640B1 (en) * 1998-07-10 2003-10-14 The United States Of America As Represented By The Secretary Of The Army Vaccine against Staphylococcus intoxication
EP1464710A3 (fr) * 2003-04-02 2004-12-22 Canon Kabushiki Kaisha Sonde et une série de sondes utilisé pour la détection des agents infectueux, un support, et une méthode de criblage genétique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000493A1 (fr) * 1992-06-29 1994-01-06 Archana Kapoor Immunogenes associes a la membrane de mycobacteries
WO1994022895A1 (fr) * 1993-04-05 1994-10-13 National Jewish Center For Immunology And Respiratory Medicine Molecule d'acide nucleique isolee codant pour des toxines associees au syndrome de kawasaki et utilisations de cette molecule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000493A1 (fr) * 1992-06-29 1994-01-06 Archana Kapoor Immunogenes associes a la membrane de mycobacteries
WO1994022895A1 (fr) * 1993-04-05 1994-10-13 National Jewish Center For Immunology And Respiratory Medicine Molecule d'acide nucleique isolee codant pour des toxines associees au syndrome de kawasaki et utilisations de cette molecule

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Database EMBL, Entry ODBETTUB, ion number L10111, 4.Febr 994; nt.1970-1991 00% homologous with Seq.ID:1 nt.2 XP002034047 *
Database EMBL, Entry SMPMI, ion number D16594, 17.Jun ; nt.519-533 a -591 are 100% homologouswith Seq.ID:1 nt.4 XP002034046 *
JOURNAL OF BACTERIOLOGY, vol. 170, no. 1, January 1988, pages 34-41, XP000676708 BETLEY AND MEKALANOS: "Nucleotide sequence of the type A staphylococcal enterotoxin gene" *
PROC. NATL. ACAD. SCI. USA, vol. 82, May 1985, pages 2583-2587, XP002034045 YOUNG ET AL.: "Dissection of Mycobacterium tuberculosis antigens using recombinant DNA" *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403337B1 (en) 1996-01-05 2002-06-11 Human Genome Sciences, Inc. Staphylococcus aureus genes and polypeptides
EP0892064A2 (fr) * 1997-06-04 1999-01-20 Smithkline Beecham Corporation Polypeptides recombinants secA2 de Staphylococcus aureus et leurs utilisations
EP0892064A3 (fr) * 1997-06-04 2000-01-12 Smithkline Beecham Corporation Polypeptides recombinants secA2 de Staphylococcus aureus et leurs utilisations
US6204019B1 (en) 1997-06-04 2001-03-20 Smithkline Beecham Corporation Sec A2 from Streptococcus pneumoniae
US6348342B1 (en) 1997-06-04 2002-02-19 Smithkline Beecham Corporation Compounds
WO1999018117A1 (fr) * 1997-10-03 1999-04-15 Smithkline Beecham Corporation 3-hydroxyacyl-coa deshydrogenase due au staphylococcus aureus
EP0913474A2 (fr) * 1997-10-28 1999-05-06 Smithkline Beecham Corporation Dbpa, une hélicase de Staphylococcus aureus
EP0913474A3 (fr) * 1997-10-28 1999-12-29 Smithkline Beecham Corporation Dbpa, une hélicase de Staphylococcus aureus
US7374931B2 (en) 1998-07-10 2008-05-20 The United States Of America As Represented By The Secretary Of The Army Vaccine against staphylococcus intoxication
US6632640B1 (en) * 1998-07-10 2003-10-14 The United States Of America As Represented By The Secretary Of The Army Vaccine against Staphylococcus intoxication
WO2003080865A1 (fr) * 2002-03-26 2003-10-02 Council Of Scientific And Industrial Research Amorces pour detecter des bacteries qui contaminent des aliments, et leur utilisation
AU2002249514B2 (en) * 2002-03-26 2008-09-04 Council Of Scientific And Industrial Research Primers for detecting food poisoning bacteria and a use thereof
AU2002249514B8 (en) * 2002-03-26 2008-10-09 Council Of Scientific And Industrial Research Primers for detecting food poisoning bacteria and a use thereof
EP1464710A3 (fr) * 2003-04-02 2004-12-22 Canon Kabushiki Kaisha Sonde et une série de sondes utilisé pour la détection des agents infectueux, un support, et une méthode de criblage genétique
EP1717323A3 (fr) * 2003-04-02 2006-12-20 Canon Kabushiki Kaisha Sonde et une série de sondes utilisé pour la détection des agents infectueux, un support, et une méthode de criblage genétique
US8080381B2 (en) 2003-04-02 2011-12-20 Canon Kabushiki Kaisha Infectious etiologic agent detection probe and probe set, carrier, and genetic screening method

Also Published As

Publication number Publication date
WO1997031114A3 (fr) 1997-10-23
GB9604045D0 (en) 1996-04-24
JPH11506022A (ja) 1999-06-02
EP0822987A2 (fr) 1998-02-11

Similar Documents

Publication Publication Date Title
US5801234A (en) Polynucleotide encoding saliva binding protein
US5858709A (en) Fibronectin binding protein B compounds
EP0837131A2 (fr) Composé contenant la protéine liant la fibronectine obtenu à partir de Staphylococcus
JP2000509246A (ja) 新規化合物
JP2000508178A (ja) 新規化合物
US20100272743A1 (en) Staphylococcus epidermidis nucleic acids and proteins
JP2000511769A (ja) 新規化合物
US7422749B2 (en) Compounds
US5965402A (en) DNA encoding phoH polypeptides
US6299880B1 (en) Cell surface protein compounds
WO1997031114A2 (fr) Polynucleotides et sequences d'acides amines provenant de staphylococcus aureus
US6180387B1 (en) Arginine deiminase
US5854020A (en) TCSTS polynucleotides
EP0811688A2 (fr) RNase P de staphylococcus aureus
US6365159B1 (en) Spo-rel
US6284515B1 (en) Signal recognition particle polypeptides and polynucleotides
US6403334B1 (en) gidB from Staphylococcus aureus
EP0902087A2 (fr) Histidine kinase
GB2306483A (en) Novel S. Aureus WCUH29 cell-surface polypeptide for use in anti-bacterial therapy and diagnosis
EP0856056A1 (fr) Composes de proteines b liant la fibronectine
US6344540B1 (en) Pai
WO1997021819A1 (fr) Nouveaux polypeptides nagpu
JP2000502563A (ja) スタフィロコッカス・アウレウス由来の２成分シグナルトランスダクションシステム
JPH10290693A (ja) 新規フィブロネクチン結合蛋白化合物
JP2000504207A (ja) スタフィロコッカス・アウレウス由来の２成分シグナルトランスダクション応答レギュレーターポリペプチド

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997905269

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 529922

Kind code of ref document: A

Format of ref document f/p: F

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1997905269

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997905269

Country of ref document: EP